# Delayed Puberty

Evaluate delayed puberty by separating constitutional and functional delay from central hypogonadism and primary gonadal failure. Growth trajectory, bone age, pubertal examination, LH/FSH, and sex steroids direct targeted evaluation, timed observation, puberty induction, and long-term replacement planning.

**Clinical question:** How should clinicians distinguish constitutional delay, functional suppression, central hypogonadism, and primary gonadal failure in adolescents with delayed puberty?

Updated: 2026-09-16T00:14:19.028820+00:00

## What matters in practice
- Evaluate girls without breast development by age 13 years and boys without apparent sexual maturation by age 14 years. [19]
- Obtain growth velocity, bone age, LH, FSH, and estradiol or testosterone as common initial tests; elevated gonadotropins direct evaluation toward primary gonadal failure, whereas low or normal values leave constitutional/functional delay versus central hypogonadism unresolved. [15][5]
- Constitutional delay is a diagnosis of exclusion; delayed bone age, short stature, family history of late puberty, and eventual acceleration in linear growth support it, but do not exclude permanent hypogonadotropic hypogonadism. [14][16][18]
- Identify and treat functional hypothalamic suppression from celiac disease, inflammatory bowel disease, kidney insufficiency, anorexia nervosa, malnutrition, or excessive exercise before labeling an adolescent as having isolated central hypogonadism. [2][14][16]
- For severe psychosocial distress in boys with likely constitutional delay, a limited course of intramuscular testosterone enanthate 50 mg monthly for 3 to 6 months is a commonly used induction regimen; reassess for spontaneous testicular enlargement after treatment. [20][22]
- Absent spontaneous puberty by age 18 years supports permanent hypogonadotropic hypogonadism rather than constitutional delay and should prompt long-term sex-steroid replacement planning. [14]

## Who requires evaluation for delayed puberty?

Use pubertal examination rather than growth concern alone to determine whether puberty has begun.

Initiate evaluation when sexual maturation has not become apparent by age 13 years in girls or age 14 years in boys. In boys, document testicular volume and penile length; in girls, document breast development. Record serial height, weight, growth velocity, and Tanner stage because growth deceleration, a stalled pubertal trajectory, or discordance between growth and sexual maturation shifts concern away from uncomplicated constitutional delay. [1][15][19]

Classify the presentation before ordering broad testing: delayed puberty may reflect transient constitutional delay of growth and puberty (CDGP), functional hypothalamic-pituitary-gonadal suppression, permanent hypogonadotropic hypogonadism, or hypergonadotropic hypogonadism from gonadal insufficiency. This branch point determines whether the next action is observation, investigation and correction of systemic disease, pituitary-hypothalamic evaluation, or gonadal-failure assessment and replacement therapy. [2][5][21]
- Ask specifically about pubertal timing in both parents; a family history of late puberty supports CDGP but does not establish it. [14][16]
- In boys, prior cryptorchidism with or without micropenis during infancy is a clue to congenital hypogonadotropic hypogonadism and should lower the threshold for endocrine referral and targeted evaluation. [13]
- Elicit restrictive intake, excessive exercise, chronic gastrointestinal symptoms, inflammatory disease, renal disease, and psychosocial factors because functional hypogonadotropic hypogonadism may reverse when the underlying condition is corrected. [2][14][16]

*Initial phenotype-based triage for delayed puberty. [2][5][14][16]*

| Clinical pattern | Most useful initial discriminators | Immediate next action |
| --- | --- | --- |
| Likely CDGP | Short stature, delayed skeletal maturation, family history of late puberty, otherwise reassuring examination and history. [14][16][18] | Obtain baseline endocrine assessment and bone age; monitor for spontaneous progression after exclusion of disease. [14][15] |
| Functional hypogonadotropic hypogonadism | Chronic disease, malnutrition, excessive exercise, anorexia nervosa, celiac disease, inflammatory bowel disease, or kidney insufficiency with low/normal gonadotropins. [2][14][16] | Evaluate and treat the underlying nutritional or systemic disorder while monitoring pubertal progression. [2][14] |
| Permanent hypogonadotropic hypogonadism | Low testosterone or estradiol with reduced LH and FSH; congenital clues include micropenis or cryptorchidism in boys. [13][14] | Assess for congenital or acquired central causes; plan sex-steroid replacement when spontaneous activation does not occur. [2][14] |
| Hypergonadotropic hypogonadism | Elevated LH and FSH indicating primary ovarian or testicular failure. [5] | Evaluate gonadal insufficiency and begin age-appropriate long-term sex-steroid replacement planning. [2][20][23] |

## What initial tests separate the major etiologic branches?

Pair biochemical testing with growth and skeletal maturation data; neither low gonadotropins nor delayed bone age is diagnostic alone.

Obtain a left hand and wrist radiograph for bone age, basal LH and FSH, and sex steroids—estradiol in girls and testosterone in boys—alongside growth-velocity assessment. Bone age is typically delayed in CDGP, and common initial assessment includes growth velocity, bone age, LH, FSH, and estradiol or testosterone. [15][16][17]

Interpret gonadotropins at the first decision point. Elevated LH and FSH indicate primary gonadal failure (hypergonadotropic hypogonadism). Low or normal LH and FSH can occur in CDGP, functional hypothalamic suppression, and congenital or acquired hypogonadotropic hypogonadism; therefore, they should trigger phenotype-based evaluation rather than reassurance. [5][13][14]

Order targeted studies according to the phenotype. Thyroxine, TSH, and IGF-1 may be appropriate when short stature or impaired growth raises concern for endocrine disease. Dynamic GnRH testing, pelvic ultrasonography to assess uterine and ovarian size, and bone age testing are reserved for selected cases because GnRH-stimulated gonadotropin responses overlap between CDGP and Kallmann syndrome or other isolated hypogonadotropic hypogonadism. [13][15][17]

Use longitudinal progression as a diagnostic test. CDGP is self-limited, with puberty beginning late but progressing normally; a definitive distinction from permanent hypogonadotropic hypogonadism may require ongoing observation, with lack of puberty by age 18 years supporting permanent hypogonadotropic hypogonadism. [2][7][14]
- Do not interpret a low basal LH or FSH as proof of central hypogonadism in a prepubertal-range adolescent; low concentrations are expected in CDGP and functional suppression. [13][14]
- In a girl with delayed puberty, pelvic ultrasonography can provide supportive information about uterine and ovarian development when the diagnosis remains uncertain. [13]
- Consider growth hormone stimulation testing when short stature warrants exclusion of growth hormone deficiency. [17]
- In suspected Kallmann syndrome, assess for congenital hypogonadotropic hypogonadism features and recognize that inhibin measurements may assist discrimination from CDGP, whereas GnRH testing is not definitive. [17]

## How do clinical patterns change management?

Treat CDGP as an exclusion diagnosis and actively search for functional, central, and gonadal causes.

CDGP is the most frequent cause of delayed puberty and is especially common in boys. The supportive pattern is short stature with delayed skeletal maturation, delayed growth before pubertal onset, a family history of late maturation, and subsequent rapid growth once puberty starts. The management consequence is observation with serial pubertal examination and growth monitoring after excluding organic disease. [13][14][16][18]

Functional hypogonadotropic hypogonadism is a potentially reversible branch. Celiac disease, inflammatory bowel disease, kidney insufficiency, anorexia nervosa, malnutrition, and excessive exercise can transiently suppress hypothalamic-pituitary-gonadal activation. In this pattern, direct the workup toward the suspected systemic or nutritional driver and reassess pubertal progression after treatment rather than committing prematurely to lifelong hormone replacement. [2][14][16]

Permanent hypogonadotropic hypogonadism produces low sex steroids with reduced LH and FSH. Congenital cases may first be recognized in adolescence but can have infant clues such as cryptorchidism or micropenis in boys. Kallmann syndrome is a form of congenital hypogonadotropic hypogonadism; differentiation from CDGP remains difficult because hormonal profiles and dynamic testing can overlap. [13][14][17]

Hypergonadotropic hypogonadism reflects gonadal failure: elevated gonadotropins distinguish it from CDGP and central causes. These patients are more likely to need long-term hormone replacement after puberty induction than patients with CDGP, in whom endogenous pubertal activation is expected. [2][5][20][23]
- Escalate beyond watchful waiting when pubertal development remains absent or fails to progress on serial examinations, when low sex steroids coexist with reduced LH/FSH, or when clinical findings suggest gonadal failure. [2][14][21]
- Treat chronic disease and nutritional compromise as active causes of delayed pubertal progression, not incidental comorbidities. [2][14][16]
- Avoid assigning CDGP solely from a delayed bone age; CDGP remains a diagnosis of exclusion. [5][14][20]

## When and how should puberty be induced?

Use short-course sex steroids for selected CDGP and gradual replacement for permanent hypogonadism.

For likely CDGP, observation and reassurance remain appropriate when psychosocial burden is limited. Consider a short course of sex steroids for marked delay or psychosocial maladaptation; treatment in CDGP should be individualized, with a particular role for adolescents older than 14 years with significant distress such as bullying, depression, low self-esteem, or school impairment. [2][20]

For boys with suspected CDGP, commonly used induction regimens include intramuscular testosterone enanthate 50 mg monthly or oral testosterone undecanoate 40 mg daily for 3 to 6 months. Transdermal options include 1% or 2% testosterone gel providing 10 mg daily or a 5-mg testosterone patch worn for 12 hours daily, although clinical experience is more limited. Reassess after the treatment course for endogenous progression, especially increasing testicular volume; a 3- to 6-month observation window after induction can allow a pubertal "jump start." [21][22]

One CDGP management approach uses intramuscular testosterone 50 mg monthly, increasing to 100 mg after 6 months when needed; treatment should be prescribed cautiously to avoid undue skeletal maturation acceleration and potential compromise of adult height. In boys receiving a trial, progressive testicular enlargement supports endogenous activation and therefore CDGP rather than permanent central hypogonadism. [20]

For girls with CDGP and selected substantial distress, limited low-dose estradiol—5 to 10 mcg daily for up to 12 months—has been described to induce breast development. In permanent hypo- or hypergonadotropic hypogonadism, use long-term sex-steroid replacement rather than repeated short trials; estrogen with progesterone is used for female hypogonadism, whereas testosterone is the primary treatment for male hypogonadism. [20][21]
- Before initiating a CDGP trial in boys, ensure the clinical assessment supports transient delay and that functional systemic causes have been addressed. [14][16][22]
- After 3 to 6 months of testosterone in a boy with suspected CDGP, assess testicular volume and clinical pubertal progression; absent physiologic puberty can justify extended monitoring or another 3- to 6-month treatment period while reevaluating for hypogonadism. [21][22]
- For boys with permanent hypogonadism in whom spermatogenesis and testicular growth are priorities, hCG with or without FSH may be more physiologic than testosterone, although testosterone remains the most widely used induction therapy. [23]

*Puberty induction choices by clinical objective. [2][20][21][22][23]*

| Patient group | Treatment approach | Reassessment that changes next step |
| --- | --- | --- |
| Likely CDGP with substantial psychosocial distress | Boy: testosterone enanthate 50 mg IM monthly or testosterone undecanoate 40 mg orally daily for 3-6 months. Girl: estradiol 5-10 mcg daily for up to 12 months in selected cases. [20][22] | Observe after treatment for spontaneous progression; increasing testicular volume in boys supports endogenous activation. [20][21][22] |
| CDGP without substantial distress | Clinical monitoring and reassurance rather than routine sex-steroid treatment. [2][20] | Initiate treatment if delay becomes marked or psychosocial morbidity develops. [2][20] |
| Permanent hypogonadotropic or hypergonadotropic hypogonadism | Gradual sex-steroid replacement, typically testosterone in males and estrogen followed by progesterone in females; long-term therapy is generally required. [2][21] | Monitor pubertal development and transition from induction to maintenance replacement. [2][21] |
| Male central hypogonadism with fertility or testicular-growth priority | Consider hCG alone or hCG plus FSH as a more physiologic strategy for spermatogenesis and testicular growth. [21][23] | Select regimen according to pubertal, testicular-growth, and fertility goals. [23] |

## How should clinicians monitor and escalate?

Serial examination is essential because time and pubertal progression remain central diagnostic discriminators.

At each follow-up, document Tanner stage, testicular volume in boys, breast development in girls, height, weight, and growth velocity. In CDGP, linear growth may remain delayed until puberty begins and then accelerates rapidly; failure of this expected clinical progression should reopen the differential for permanent hypogonadism or systemic disease. [1][14][16]

After a 3- to 6-month induction course for presumed CDGP, allow a 3- to 6-month observation interval to detect autonomous pubertal progression. In boys, a rise in testicular volume to approximately 6 to 8 mL indicates significant hypothalamic-pituitary-gonadal axis activation; absent progression after limited trials should prompt reassessment for permanent hypogonadism and planning for long-term replacement. [21][22]

Continue endocrine follow-up through completion of pubertal development in permanent hypo- or hypergonadotropic hypogonadism. These adolescents usually require ongoing hormone replacement after induction, whereas CDGP treatment can be discontinued once endogenous puberty is established. [2][20][21]
- Escalate diagnostic reassessment if a presumed CDGP patient has no spontaneous pubertal development by age 18 years. [14]
- Reassess systemic and nutritional contributors whenever growth velocity worsens or pubertal progression stalls. [2][14][16]
- Use serial testicular volume rather than serum testosterone alone to judge endogenous pubertal activation after a testosterone trial in boys. [20][21][22]

## References
1. [PDF] BRIEFING BOOK FOR Pediatric Advisory Committee (PAC) - FDA — www.fda.gov — https://www.fda.gov/media/122563/download
2. Delayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/1126
3. Delayed Puberty and Hypogonadism Caused by Mutations in the ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199708283370905
4. Male pubertal development and the role of androgen therapy | Nature Reviews Endocrinology — www.nature.com — https://www.nature.com/articles/ncpendmet0450
5. Delayed Puberty - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/delayed-puberty
6. Review of Hormone Replacement Therapy in Girls and Adolescents with Hypogonadism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1083318819301834
7. Constitutional delay of puberty versus congenital hypogonadotropic ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1521690X19300673
8. Management of hypogonadism from birth to adolescence - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521690X18300794
9. Monogenic Disorders of Puberty - Oxford Academic — academic.oup.com — https://academic.oup.com/jcem/article/87/6/2481/2846595
10. Clinical Management of Congenital Hypogonadotropic Hypogonadism — academic.oup.com — https://academic.oup.com/edrv/article/40/2/669/5303368
11. Mini-Puberty, Physiological and Disordered - Oxford Academic — academic.oup.com — https://academic.oup.com/edrv/article/45/4/460/7618576
12. Adolescent Anovulation: Maturational Mechanisms and ... — academic.oup.com — https://academic.oup.com/jcem/article/98/9/3572/2833078
13. Delayed puberty versus hypogonadism: a challenge for the pediatrician - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057016?term=
14. Current clinical management of constitutional delay of growth and puberty - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/35331309
15. PUBERTY: NORMAL AND ABNORMAL - AAP Publications — publications.aap.org — https://publications.aap.org/book/chapter-pdf/1337933/aap_9781610020473-part06-ch185.pdf
16. Delayed puberty versus hypogonadism: a challenge for the pediatrician - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/29969875
17. Kallmann Syndrome - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK538210
18. Puberty: Normal and Abnormal (Chapter 185) - AAP Publications — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5774677/Puberty-Normal-and-Abnormal-Chapter-185
19. Delayed Puberty - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/article-pdf/22/9/309/992386/pir309.pdf
20. Current clinical management of constitutional delay of growth and puberty — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8944060
21. A Current Perspective on Delayed Puberty and Its Management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11629716
22. Testosterone Use in Adolescent Males: Current Practice and Unmet Needs — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7705876
23. Puberty Induction in Adolescent Males: Current Practice — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9073269
24. Current clinical management of constitutional delay of growth and puberty. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/35331309

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.